Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2002 19
2003 30
2004 43
2005 60
2006 69
2007 66
2008 77
2009 85
2010 111
2011 119
2012 149
2013 141
2014 162
2015 165
2016 145
2017 194
2018 235
2019 257
2020 308
2021 357
2022 444
2023 419
2024 497
2025 134

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,798 results

Results by year

Filters applied: . Clear all
Page 1
ERK/MAPK signalling pathway and tumorigenesis.
Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. Guo YJ, et al. Among authors: xu y. Exp Ther Med. 2020 Mar;19(3):1997-2007. doi: 10.3892/etm.2020.8454. Epub 2020 Jan 15. Exp Ther Med. 2020. PMID: 32104259 Free PMC article. Review.
PCR past, present and future.
Zhu H, Zhang H, Xu Y, Laššáková S, Korabečná M, Neužil P. Zhu H, et al. Among authors: xu y. Biotechniques. 2020 Oct;69(4):317-325. doi: 10.2144/btn-2020-0057. Epub 2020 Aug 20. Biotechniques. 2020. PMID: 32815744 Free PMC article. Review.
Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1.
Xu H, Zhao H, Ding C, Jiang D, Zhao Z, Li Y, Ding X, Gao J, Zhou H, Luo C, Chen G, Zhang A, Xu Y, Zhang H. Xu H, et al. Among authors: xu y. Signal Transduct Target Ther. 2023 Feb 3;8(1):51. doi: 10.1038/s41392-022-01231-4. Signal Transduct Target Ther. 2023. PMID: 36732502 Free PMC article.
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Chen L, Jiang YZ, Wu SY, Wu J, Di GH, Liu GY, Yu KD, Fan L, Li JJ, Hou YF, Hu Z, Chen CM, Huang XY, Cao AY, Hu X, Zhao S, Ma XY, Xu Y, Sun XJ, Chai WJ, Guo X, Chen X, Xu Y, Zhu XY, Zou JJ, Yang WT, Wang ZH, Shao ZM. Chen L, et al. Among authors: xu y. Clin Cancer Res. 2022 Jul 1;28(13):2807-2817. doi: 10.1158/1078-0432.CCR-21-4313. Clin Cancer Res. 2022. PMID: 35247906 Free PMC article.
3,798 results